Get started
Author

Heather Kinkead

Observed institution: Inhibrx (United States)
ORCID: 0009-0004-7981-2243
Observed ORCID: 0009-0004-7981-2243
OpenAlex ID: A5126604173
Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors
2026 · Jong Chul Park, David Berz, et al. · Cancer Research Communications · 1
PDF
Table S5 from Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors
2026 · Jong Chul Park, David Berz, et al.
Table S1 from Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors
2026 · Jong Chul Park, David Berz, et al.
Figure S5 from Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors
2026 · Jong Chul Park, David Berz, et al.
Figure S1 from Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors
2026 · Jong Chul Park, David Berz, et al.
Table S2 from Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors
2026 · Jong Chul Park, David Berz, et al.
Figure S2 from Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors
2026 · Jong Chul Park, David Berz, et al.
Table S7 from Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors
2026 · Jong Chul Park, David Berz, et al.
Table S4 from Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors
2026 · Jong Chul Park, David Berz, et al.
Figure S4 from Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors
2026 · Jong Chul Park, David Berz, et al.
Figure S3 from Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors
2026 · Jong Chul Park, David Berz, et al.
Table S3 from Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors
2026 · Jong Chul Park, David Berz, et al.
Table S6 from Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors
2026 · Jong Chul Park, David Berz, et al.
Table S3 from Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors
2026 · Jong Chul Park, David Berz, et al.
Figure S3 from Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors
2026 · Jong Chul Park, David Berz, et al.
Table S1 from Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors
2026 · Jong Chul Park, David Berz, et al.
Table S6 from Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors
2026 · Jong Chul Park, David Berz, et al.
Figure S2 from Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors
2026 · Jong Chul Park, David Berz, et al.
Figure 2 from Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors
2026 · Jong Chul Park, David Berz, et al.
Table S7 from Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors
2026 · Jong Chul Park, David Berz, et al.
Table 1 from Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors
2026 · Jong Chul Park, David Berz, et al.
Figure 1 from Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors
2026 · Jong Chul Park, David Berz, et al.
Figure S5 from Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors
2026 · Jong Chul Park, David Berz, et al.
Table 3 from Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors
2026 · Jong Chul Park, David Berz, et al.
Table S5 from Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors
2026 · Jong Chul Park, David Berz, et al.
Works count: 31
Citation count: 1
H-index: 1
I10-index:
Year
Topic
Type